Yonatan Malca - 15 Jan 2025 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role
Director
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Issuer symbol
ENTX
Transactions as of
15 Jan 2025
Net transactions value
$0
Form type
4
Filing time
17 Jan 2025, 16:31:36 UTC
Previous filing
04 Oct 2024
Next filing
02 Jan 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTX Ordinary Shares, par value NIS 0.0000769 per share Award $0 +8,216 +21% $0.000000 47,259 15 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTX Stock Option (right to buy) Award $0 +28,509 $0.000000 28,509 15 Jan 2025 Ordinary Shares, par value NIS 0.0000769 per share 28,509 $2.28 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.
F2 These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2025.